About

Born: 1980

Appointed: April 5, 2017.

Qualifications: M.Sc. Automation Engineering, Master’s Degree in Business Development. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.

Experience: Fredrik has got 20 years of experience from management positions in the life science industry. Previously the CEO of Inhalation Sciences, Hemcheck, Lipopeptide and PharmaSurgics.

Current roles: Currently Chairman at the public companies Lipidor and Monivent. Also Chairman of Emollivet and board member of Phargentis.

Ownership: 178 000 shares and 42 200 warrants

Born: 1976

Appointed: 20 Maj 2019.

Qualifications: MSc Molecular Biology. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.

Experience: Mikaela has 20 years of experience working at major global life-science companies. She has held several strategic commercial roles and senior management positions in the Nordic region, on global and HQ level. During 1999-2008, various commercial roles with MSD Sweden AB, 2008-2012 local marketing and strategic roles with AstraZeneca Sweden and Nordic-Baltic. From 2012 to 2015 she was the Global Head of Astra Zeneca’s Vaccine Franchise, from 2015-2019 Vice President of Nordic-Baltic Business Unit in Respiratory, Inflammation and Autoimmune disease (RIA). Since Aug 2019 Head of Nordic Region for Real World Evidence at IQVIA.

Ownership: 9 000 shares and 42 200 warrants

Born: 1975.

Appointed: Joined Ziccum August 2019, appointed Senior Formulation Specialist July 2020, appointed Scientific Director August 2022.

Qualifications: BSc in Pharmaceutical Development and Production at the Conservatoire National des Arts et Métiers Conservatoire, Paris. DEUST in Production and Quality in Pharmaceutical Industries, Formulation and Control quality, Aix-Marseille University, Marseille.

Experience: Fabrice is the author or co-author of 16 peer-reviewed publications on vaccine formulation. His 20 years’ plus experience in formulation and drug delivery includes ten year’s lab work specializing in the design and characterization of nanoparticulate vaccine formulations and investigating the physical stability of protein antigens. Highly result-oriented, Fabrice’s extensive industry experience has been characterized by his determination, resourcefulness and commitment to solving new challenges with a creative and strategic mindset.

Previous roles: Fabrice has extensive industrial and academic experience in formulation. He was a Laboratory specialist at the University of Copenhagen’s Faculty of Health and Medical Sciences, designing and characterizing vaccine formulations. He was a scientist at SOLVE contract analytical lab (running specialized analytical instrumentation), he worked at Catalent (the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products) in formulation, preformulation and stability studies for oral dosage forms, as well as other roles throughout Europe.

Ownership: 1000 warrants.

Born: 1967

Appointed: April 28, 2022

Qualifications: Ph.D. Biophysics. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: 20 years of experience from executive roles in fast-growing Life Science companies, with a focus on management, strategy, business- and team development. Previous roles include Chief Operating Officer & Chief Digital Officer at Atlas Antibodies, a Swedish biotech company active in the field of advanced research reagents, Manager at Sidec AB, a contract research company with global pharma and biotech clients, and Business development consultant at Banyay Consulting AB.

Current roles: Chief Executive Officer at VivoLogica AB.

Ownership: 3 000 shares and 33 000 warrants

Born: 1961

Appointed: April 28, 2022

Qualifications: Technical doctor in physical chemistry from KTH and an MBA from Stockholm University. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum. She was previously CEO for Modus Therapeutics and have been on senior positions on Swedish Orphan Biovitrum AB (Sobi) and Biovitrum.

Experience: More than 25 years of experience of drug- and business development withing the pharma industry.

Current roles: Executive Vice President, Strategic Business Development at Medivir AB. She is also a board member in PCI Biotech Holding, Idogen AB and Elicera Therapeutics.

Ownership: No shares and 33 000 warrants

Born: 1966.

Appointed: May 9, 2022.

Qualifications: MSc Chemical Engineering Bioprocessing, Lund University and École Nationale Supérieure d’Ingénieurs de Génie Chimique de Toulouse. MBA, Lund University. Diplôme de Francais, Étoile, Paris.

Experience: Ann has 25+ years of experience from Life Science management internationally, with a significant track record in strategic development, focused leadship, deal making and sales growth. Generating steep growth in leading, international Pharma CDMO corporations took her to senior global positions in the US and Germany. She has also been leading internationalization of mid-sized Life Science companies in Sweden and Germany, as well as building up Pharma technology licencing internationally. Recent years have given experience from CEO and Board positions in listed Swedish Life Science start-ups.

Previous roles: Previous to Ziccum, Ann was the CEO of SelectImmune Pharma AB, AcuCort AB and Monocl AB, as well as Head of the Inceptua CTS Business unit in Berlin, Germany and Licensing Director at Novozymes Biopharma in Copenhagen, Denmark. Furthermore, she held senior Global Business Development and Sales & Marketing Director roles in Cambrex Corp based in New Jersey, USA and Lanxess GmbH in Leverkusen, Germany. She has also been in Pharmaceutical manufacturing and Engineering management roles. Currently Ann holds a board position in Iconovo AB, after SenzaGen AB.

Ownership: 75 000 shares and 100 000 warrants.

Born: 1984.

Appointed: January 1, 2021.

Qualifications: MBA (Master Business Administration), Lund University and Hong Kong University of Science and Technology.

Experience: Frida is an experienced CFO with a strong background in controlling, accounting and auditing. She has extensive leadership and management experience, successfully leading major projects in outsourcing, acquisitions, mergers, restructuring and systems implementations.

Previous roles: Prior to Ziccum, Frida was CFO for Spares Nordic, a growth company in e-commerce. Previously, Frida has occupied a wide range of management and executive positions, including Head of Accounting at Egmont, Business Controller and Financial Analyst at RSA Insurance Group (Codan/Trygg-Hansa) and Auditor at KPMG.

Ownership: 1 900 shares and 39 364 warrants.